drugset / Trial / NCT01923545
Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | G-CSF | Unknown | 100 ug/m2 | — |
| Subject | Pegfilgrastim | Protein / enzyme biologic | 3.6 mg | — |
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | — |